Skip to main content
Erschienen in: Clinical Drug Investigation 7/2013

01.07.2013 | Original Research Article

Developmental Changes in Morphine Clearance Across the Entire Paediatric Age Range are Best Described by a Bodyweight-Dependent Exponent Model

verfasst von: Chenguang Wang, Senthilkumar Sadhavisvam, Elke H. J. Krekels, Albert Dahan, Dick Tibboel, Meindert Danhof, Alexander A. Vinks, Catherijne A. J. Knibbe

Erschienen in: Clinical Drug Investigation | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

Morphine clearance has been successfully scaled from preterm neonates to 3-year-old children on the basis of a bodyweight-based exponential (BDE) function and age younger or older than 10 days. The aim of the current study was to characterize the developmental changes in morphine clearance across the entire paediatric age range.

Methods

Morphine and morphine-3-glucuronide (M3G) concentration data from 358 (pre)term neonates, infants, children and adults, and morphine concentration data from 117 adolescents were analysed using NONMEM 7.2. Based on available data, two models were developed: I. using morphine data; II. using morphine and M3G data.

Results

In model I, morphine clearance across the paediatric age range was very well described by a BDE function in which the allometric exponent decreased in a sigmoidal manner with bodyweight (BDE model) from 1.47 to 0.88, with half the decrease in exponent reached at 4.01 kg. In model II, the exponent for the formation and elimination clearance of M3G was found to decrease from 1.56 to 0.89 and from 1.06 to 0.61, with half the decrease reached at 3.89 and 4.87 kg, respectively. Using the BDE model, there was no need to use additional measures for size or age.

Conclusion

The BDE model was able to scale both total morphine clearance and glucuronidation clearance through the M3G pathway across all age ranges between (pre)term neonates and adults by allowing the allometric exponent to decrease across the paediatric age range from values higher than 1 for neonates to values lower than 1 for infants and children.
Literatur
1.
Zurück zum Zitat Krekels EH, Tibboel D, Danhof M, Knibbe CA. Prediction of morphine clearance in the paediatric population: how accurate are the available pharmacokinetic models? Clin Pharmacokinet. 2012;51(11):695–709. doi:10.1007/s40262-012-0006-9.PubMedCrossRef Krekels EH, Tibboel D, Danhof M, Knibbe CA. Prediction of morphine clearance in the paediatric population: how accurate are the available pharmacokinetic models? Clin Pharmacokinet. 2012;51(11):695–709. doi:10.​1007/​s40262-012-0006-9.PubMedCrossRef
2.
Zurück zum Zitat Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth. 2004;92(2):208–17.PubMedCrossRef Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth. 2004;92(2):208–17.PubMedCrossRef
3.
Zurück zum Zitat Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth. 2008;101(5):680–9. doi:aen24810.1093/bja/aen248.PubMedCrossRef Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth. 2008;101(5):680–9. doi:aen24810.​1093/​bja/​aen248.PubMedCrossRef
5.
Zurück zum Zitat Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28(4):797–811. doi:10.1007/s11095-010-0333-1.PubMedCrossRef Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28(4):797–811. doi:10.​1007/​s11095-010-0333-1.PubMedCrossRef
8.
Zurück zum Zitat Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res. 1999;16(5):709–17.PubMedCrossRef Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res. 1999;16(5):709–17.PubMedCrossRef
9.
Zurück zum Zitat Khandelwal A, et al. Influence of correlated covariates on predictive performance for different models. 2011; Abstr 2220:20, 2011. Khandelwal A, et al. Influence of correlated covariates on predictive performance for different models. 2011; Abstr 2220:20, 2011.
10.
Zurück zum Zitat Krekels EH, DeJongh J, van Lingen RA, van der Marel CD, Choonara I, Lynn AM, et al. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet. 2011;50(1):51–63. doi:10.2165/11536750-000000000-00000.PubMedCrossRef Krekels EH, DeJongh J, van Lingen RA, van der Marel CD, Choonara I, Lynn AM, et al. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet. 2011;50(1):51–63. doi:10.​2165/​11536750-000000000-00000.PubMedCrossRef
11.
Zurück zum Zitat Wang C, Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Krekels EH, Tibboel D, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012. doi:10.1007/s11095-012-0668-x. Wang C, Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Krekels EH, Tibboel D, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012. doi:10.​1007/​s11095-012-0668-x.
12.
Zurück zum Zitat Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51(5):331–45. doi:10.2165/11598180-000000000-00000.PubMedCrossRef Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51(5):331–45. doi:10.​2165/​11598180-000000000-00000.PubMedCrossRef
13.
Zurück zum Zitat van Dijk M, Bouwmeester NJ, Duivenvoorden HJ, Koot HM, Tibboel D, Passchier J, et al. Efficacy of continuous versus intermittent morphine administration after major surgery in 0–3-year-old infants; a double-blind randomized controlled trial. Pain. 2002;98(3):305–13.PubMedCrossRef van Dijk M, Bouwmeester NJ, Duivenvoorden HJ, Koot HM, Tibboel D, Passchier J, et al. Efficacy of continuous versus intermittent morphine administration after major surgery in 0–3-year-old infants; a double-blind randomized controlled trial. Pain. 2002;98(3):305–13.PubMedCrossRef
14.
Zurück zum Zitat Simons SH, van Dijk M, van Lingen RA, Roofthooft D, Duivenvoorden HJ, Jongeneel N, et al. Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial. JAMA. 2003;290(18):2419–27. doi:10.1001/jama.290.18.2419.PubMedCrossRef Simons SH, van Dijk M, van Lingen RA, Roofthooft D, Duivenvoorden HJ, Jongeneel N, et al. Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial. JAMA. 2003;290(18):2419–27. doi:10.​1001/​jama.​290.​18.​2419.PubMedCrossRef
15.
Zurück zum Zitat van Lingen RA. Pain assessment and analgesia in the newborn: an integrated approach. Rotterdam: Erasmus University; 2000. van Lingen RA. Pain assessment and analgesia in the newborn: an integrated approach. Rotterdam: Erasmus University; 2000.
16.
Zurück zum Zitat van der Marel CD, Peters JW, Bouwmeester NJ, Jacqz-Aigrain E, van den Anker JN, Tibboel D. Rectal acetaminophen does not reduce morphine consumption after major surgery in young infants. Br J Anaesth. 2007;98(3):372–9. doi:10.1093/bja/ael371.PubMedCrossRef van der Marel CD, Peters JW, Bouwmeester NJ, Jacqz-Aigrain E, van den Anker JN, Tibboel D. Rectal acetaminophen does not reduce morphine consumption after major surgery in young infants. Br J Anaesth. 2007;98(3):372–9. doi:10.​1093/​bja/​ael371.PubMedCrossRef
17.
Zurück zum Zitat Lynn AM, Nespeca MK, Bratton SL, Shen DD. Intravenous morphine in postoperative infants: intermittent bolus dosing versus targeted continuous infusions. Pain. 2000;88(1):89–95.PubMedCrossRef Lynn AM, Nespeca MK, Bratton SL, Shen DD. Intravenous morphine in postoperative infants: intermittent bolus dosing versus targeted continuous infusions. Pain. 2000;88(1):89–95.PubMedCrossRef
18.
Zurück zum Zitat Choonara I, Lawrence A, Michalkiewicz A, Bowhay A, Ratcliffe J. Morphine metabolism in neonates and infants. Br J Clin Pharmacol. 1992;34(5):434–7.PubMedCrossRef Choonara I, Lawrence A, Michalkiewicz A, Bowhay A, Ratcliffe J. Morphine metabolism in neonates and infants. Br J Clin Pharmacol. 1992;34(5):434–7.PubMedCrossRef
19.
Zurück zum Zitat Sadhasivam S, Krekels EH, Chidambaran V, Esslinger HR, Ngamprasertwong P, Zhang K, et al. Morphine clearance in children: does race or genetics matter? J Opioid Manage. 2012;8(4):217–26. doi:10.5055/jom.2012.0119.CrossRef Sadhasivam S, Krekels EH, Chidambaran V, Esslinger HR, Ngamprasertwong P, Zhang K, et al. Morphine clearance in children: does race or genetics matter? J Opioid Manage. 2012;8(4):217–26. doi:10.​5055/​jom.​2012.​0119.CrossRef
20.
Zurück zum Zitat Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuijs D, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology. 2000;93(5):1245–54; discussion 6A. Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuijs D, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology. 2000;93(5):1245–54; discussion 6A.
22.
23.
Zurück zum Zitat Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML. Limited phase I study of morphine-3-glucuronide. J Pharm Sci. 2001;90(11):1810–6.PubMedCrossRef Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML. Limited phase I study of morphine-3-glucuronide. J Pharm Sci. 2001;90(11):1810–6.PubMedCrossRef
24.
Zurück zum Zitat Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50(2):259–65.PubMedCrossRef Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002;50(2):259–65.PubMedCrossRef
25.
Zurück zum Zitat Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006;45(7):683–704.PubMedCrossRef Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006;45(7):683–704.PubMedCrossRef
28.
Zurück zum Zitat Krekels EHJ, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, et al. From pediatric covariate model to semiphysiological function for maturation: Part II-sensitivity to physiological and physicochemical properties. CPT Pharmacomet Syst Pharmacol. 2012;1:e10. Krekels EHJ, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, et al. From pediatric covariate model to semiphysiological function for maturation: Part II-sensitivity to physiological and physicochemical properties. CPT Pharmacomet Syst Pharmacol. 2012;1:e10.
30.
Zurück zum Zitat Ince I, de Wildt SN, Wang C,0020Peeters MY, Burggraaf J, Jacqz-Aigrain E, et al. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. Clin Pharmacokinet. 2013. doi:10.1007/s40262-013-0050-0. Ince I, de Wildt SN, Wang C,0020Peeters MY, Burggraaf J, Jacqz-Aigrain E, et al. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. Clin Pharmacokinet. 2013. doi:10.​1007/​s40262-013-0050-0.
Metadaten
Titel
Developmental Changes in Morphine Clearance Across the Entire Paediatric Age Range are Best Described by a Bodyweight-Dependent Exponent Model
verfasst von
Chenguang Wang
Senthilkumar Sadhavisvam
Elke H. J. Krekels
Albert Dahan
Dick Tibboel
Meindert Danhof
Alexander A. Vinks
Catherijne A. J. Knibbe
Publikationsdatum
01.07.2013
Verlag
Springer International Publishing AG
Erschienen in
Clinical Drug Investigation / Ausgabe 7/2013
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-013-0097-6

Weitere Artikel der Ausgabe 7/2013

Clinical Drug Investigation 7/2013 Zur Ausgabe